DUPILUMAB EFFICACY AND SAFETY UP TO 52 WEEKS IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM PART A AND C OF A RANDOMIZED, PLACEBO-CONTROLLED, THREE-PART, PHASE 3 LIBERTY EOE TREET STUDY

Evan S. Dellon  ¹     Marc E. Rothenberg  ²     Albert J. Bredenoord  ³     Qiong Zhao  ⁴     Urvi Mujumdar  ⁵     Siddhesh Kamat     Bolanle Akinlade     Elizabeth Laws  ⁶     Nikhil Amin     Paul J. Rowe     Yamo Deniz     Juby A. Jacob-Nara     Kiran Patel     Veronica Mas Casullo     Leda Mannent  ⁷     Jonathan Spergel  ^8    
1 University of North Carolina School of Medicine, Chapel Hill, United States
² Cincinnati Children's Hospital and University of Cincinnati College of Medicine, Cincinnati, United States
³ Amsterdam University Medical Center, Amsterdam, Netherlands
⁴ Regeneron Pharmaceuticals, Inc, Tarrytown, United States
⁵ Sanofi, Cambridge, United States
⁶ Sanofi, Bridgewater, United States
⁷ Sanofi, Chilly-Mazarin, France
⁸ Children's Hospital of Philadelphia, Philadelphia, United States

Topic
IBD

Session
Late-breaking Abstracts II: Upper GI and IBD

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)